Observational studyInterdisciplinary cardiovascular and thoracic surgery2026
Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.
Observational study in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImpella 5.5 is an established temporary mechanical circulatory support (tMCS) device for severe cardiogenic shock. Spain, characterized by high heart transplant activity and increasing use of controlled donation after circulatory death (DCD), provides a relevant setting to evaluate its use and outcomes. We aimed to describe clinical characteristics, trajectories, and outcomes of Impella 5.5 support in the first Spanish multicentre cohort from heart transplant centres.
methodsRetrospective multicentre observational study including consecutive patients supported with Impella 5.5 in hospitals with active heart transplant programmes. Baseline characteristics, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, additional support, complications, support duration, and in-hospital mortality were recorded. Outcomes were analysed across INTERMACS profiles.
resultsNinety-three patients were included (33 INTERMACS 1, 37 INTERMACS 2, 23 INTERMACS 3). Additional support was required in 46%, mainly venoarterial extracorporeal life support (VA-ECLS). Device-related complications were reported as event frequencies. The predominant clinical trajectory was heart transplantation (68.8%), contrasting with international series in which long-term mechanical support and transplantation are more evenly distributed. In-hospital mortality was 43%, with a clear gradient across INTERMACS profiles 1-3 (60.6%, 37.8%, and 26.1%, respectively; P = .013). Mean support duration was 16 days, and more than one-third of transplants were from controlled DCD donors.
conclusionsImpella 5.5 was used as tMCS in severe cardiogenic shock and was predominantly associated with heart transplantation in a transplant-oriented healthcare system. Outcomes were closely associated with INTERMACS profile, reflecting differences in baseline severity and patient selection. Comparisons with international registries are descriptive only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.